Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
04/2003
04/01/2003US6540977 Cyanidin compositions and therapeutic and diagnostic uses therefor
04/01/2003CA2405918A1 Controlled release macrolide pharmaceutical formulations
04/01/2003CA2290906C Causative agent of the mystery swine disease, vaccine compositions and diagnostic kits
04/01/2003CA2235951C Novel uses of mammalian ctla-8 and related reagents
04/01/2003CA2101070C Antigen-presenting capsid with fusion ms2-coat protein
04/01/2003CA2044676C Pharmaceutical composition for rectal administration of active principles exhibiting a prevalently topical medication action at the colon level
03/2003
03/27/2003WO2003025542A2 Immune response associated proteins
03/27/2003WO2003025218A2 Methods and yeast strains for screening antifungal agents
03/27/2003WO2003025199A2 Mid 4460, a human tyrosine phosphatase family member and uses therefor
03/27/2003WO2003025177A2 Sequences involved in phenomena of tumour suppression, tumour reversion, adoptosis and/or resistance to viruses and the use thereof as medicaments
03/27/2003WO2003025176A2 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
03/27/2003WO2003025173A1 Novel antisense oligonucleotide derivatives to hepatitis c virus
03/27/2003WO2003025151A2 Circadian control of stem/progenitor cell self-renewal and differentiation and of clock controlled gene expression
03/27/2003WO2003025131A2 Protein modification and maintenance molecules
03/27/2003WO2003025119A2 Compositions comprising immunostimulatory oligonucleotides and uses thereof to enhance fc receptor-mediated immunotherapies
03/27/2003WO2003025018A2 Dimeric and multimeric antigen binding structure
03/27/2003WO2003025017A1 Cytokine receptor
03/27/2003WO2003025014A2 Use of peptides comprising post-translational modifications in the treatment of autoimmune pathologies
03/27/2003WO2003025003A2 Hiv-gag codon-optimised dna vaccines
03/27/2003WO2003024996A2 Antibacterial macrocycles
03/27/2003WO2003024995A1 Molecules that block viral infectivity and methods of use thereof
03/27/2003WO2003024986A1 6-o-carbamate-11,12-lacto-ketolide antimicrobials
03/27/2003WO2003024973A1 Spirocyclic-6,7-dihydro-5h-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines
03/27/2003WO2003024971A1 6,7-dihydro-5h-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines
03/27/2003WO2003024970A1 Compounds which inhibit the release of inflammatory cytokines
03/27/2003WO2003024966A1 Pteridinone derivatives as modulators of chemokine receptor activity
03/27/2003WO2003024952A1 Bioprecursors for percutaneous application
03/27/2003WO2003024949A1 Dna-pk inhibitors
03/27/2003WO2003024941A1 Naphthalene compounds and use thereof as drugs
03/27/2003WO2003024922A1 Hydroxyfattysulfonic acid analogs
03/27/2003WO2003024920A1 Substituted urea retinoid agonists ii
03/27/2003WO2003024913A1 SUBSTITUTED BENZOIC ACID DERIVATIVES EXHIBITING NF-κB INHIBITING ACTIVITY
03/27/2003WO2003024528A1 Systematical administration of some oxazolidinones, e.g. linezolid, for the treatment for ocular infections
03/27/2003WO2003024482A1 Crustaceans as production systems for therapeutic proteins
03/27/2003WO2003024481A2 Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
03/27/2003WO2003024480A2 In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
03/27/2003WO2003024479A1 Enamel matrix protein compositions for modulating immune response
03/27/2003WO2003024461A1 Hcv combination therapy
03/27/2003WO2003024455A2 Stent coated with a sustained-release drug delivery and method for use thereof
03/27/2003WO2003024437A1 Allicin
03/27/2003WO2003024424A1 Stabilization of active agents by formulation into nanoparticulate form
03/27/2003WO2003024404A2 Chemokines as adjuvants of immune response
03/27/2003WO2003024395A2 Linked biaryl compounds
03/27/2003WO2003024390A2 Hydroxyeicosenoic acid analogs
03/27/2003WO2003024357A2 Microfabricated nanopore device for sustained release of therapeutic agent
03/27/2003WO2003024354A2 Interleukin-12 as a veterinary vaccine adjuvant
03/27/2003WO2003024223A1 Pesticidal formulations
03/27/2003WO2003002553A3 Fluoropyrrolidines as dipeptidyl peptidase inhibitors
03/27/2003WO2002094263A3 Caspase inhibitors and uses thereof
03/27/2003WO2002094019A9 Highly purified antiendotoxin compound
03/27/2003WO2002083870A3 Pufa polyketide synthase systems and uses thereof
03/27/2003WO2002078628A3 Cyanamide, alkoxyamino, and urea derivatives of 1,3-benzodiazapines as hiv reverse transcriptase inhibitors
03/27/2003WO2002060879A3 Bacterial gyrase inhibitors and uses thereof
03/27/2003WO2002060859A3 Cyclic derivatives as modulators of chemokine receptor activity
03/27/2003WO2002059291A3 Biological organism for preparing pharmaceutical compositions for treating mammals
03/27/2003WO2002056829A3 Methods for preparing purified daptomycin
03/27/2003WO2002055100A3 Method and composition for inhibition of tumor growth and enhancing an immune response
03/27/2003WO2002054868A3 Pulmonary delivery of polyene antifungal agents
03/27/2003WO2002053761A3 Recombinant protective protein from $i(streptococcus pneumoniae)
03/27/2003WO2002053100A3 Pharmaceutical dosage form for oral administration of low molecular weight heparin
03/27/2003WO2002048358A3 Regulation of human chemokine-like receptor
03/27/2003WO2002048147A3 Pyrazolopyridines
03/27/2003WO2002026219A3 Otic microbial combinations for treatment of animals with ruptured tympanic membrane
03/27/2003WO2002026212A3 Microparticle compositions and methods for the manufacture thereof
03/27/2003WO2002020050A9 Eiav p26 deletion vaccine and diagnostic
03/27/2003WO2002018954A9 Inhibition of cmv infection and dissemination
03/27/2003WO2002014261A3 4-substituted d-glutamic acid derivatives for use as antibiotic
03/27/2003WO2002012340A3 Transporters and ion channels
03/27/2003WO2002009750A3 Vaccines for equine herpesvirus type-1: viruses harboring mutations within the immediate early gene
03/27/2003WO2002000692A3 Pd-l2 molecules: pd-1 ligands and uses therefor
03/27/2003WO2001092218A3 Polyamine analogues as therapeutic and diagnostic agents
03/27/2003WO2001083794A3 Dna transfection system for the generation of infectious influenza virus
03/27/2003US20030060873 Providing an electrochemical solution comprising metal and bioactive material; contacting electrochemical solution and substrate; forming a bioactive composite structure on substrate using an electrochemical procedure
03/27/2003US20030060645 Polymorphic and other crystalline forms cis-FTC
03/27/2003US20030060635 Methods of using bis-indolylquinones
03/27/2003US20030060609 For use as antibiotics
03/27/2003US20030060598 Glycopeptide derivatives and pharmaceutical compositions containing the same
03/27/2003US20030060492 Nitrosated and nitrosylated H2 receptor antagonist compounds, compositions and methods of use
03/27/2003US20030060485 (+)-norcisapride
03/27/2003US20030060482 Urease inhibitors
03/27/2003US20030060469 Use of substances that act as cascade inhibitors of the raf/mek/erk signal cascade, for producing a medicament to treat dna and rna viruses
03/27/2003US20030060459 Diamines as modulators of chemokine receptor activity
03/27/2003US20030060455 Treating lung damage from smoke, endometriosis, Behcet's disease, ankylosing spondylitis, cancer, Lyme disease, and/or restenosis following agioplasty with 1-(4-t-butyl-phenyl)-3-(4-(6-morpholin-4-ylmethyl-peperidin-yl)naphthalen-1 -yl)-urea
03/27/2003US20030060442 Immunostimulatory cyktokines include interleukins as antitumor agents, dervived from dendritic cells modified via viral vector transduction/centrifugation
03/27/2003US20030060431 Base analogues
03/27/2003US20030060410 Use of HMG fragments as anti-inflammatory agents
03/27/2003US20030060400 A modified nucleoside comprising a purine or pyrimidine ring for treating viral infections
03/27/2003US20030059944 Method for expression of small antiviral RNA molecules within a cell
03/27/2003US20030059943 Inhibition of gene expression in preferential cell; obtain cells, infect with viral particles, recover infected cells, express viral sequences, monitor adjustment in gene expression
03/27/2003US20030059916 IRAK-4: compositions and methods of use
03/27/2003US20030059896 Nucleotide sequences coding polypeptide for use in the diagnosis and detection of chlamydial infcetions
03/27/2003US20030059894 Nucleotide sequences coding polypeptide for use in the treatment, prevention and diagnosis of lyme disease
03/27/2003US20030059874 Polypeptide for use in the treatment of autoimmune, inflammatatory, arthritic, atherosclerotic, allergenic, dermatitis, urticaria, adult respiratory distress syndrome, asthma, rhinitis, eczema and infections
03/27/2003US20030059862 Antibodies against tumor necrosis factor delta (APRIL)
03/27/2003US20030059856 Detection of modulator of receptor binding activity; obtain sample containing receptor, incubate with test agent and ligand, monitor binding activity of ligand, adjusment in binding activity indicates modulator
03/27/2003US20030059802 Nucleotide sequences coding polypeptide for use in the prevention and treatment of infection of gut and intestine; for use aide in digestion and nutrient absorption
03/27/2003US20030059799 Modified DNA molecule, recombinant containing the same, and uses thereof
03/27/2003US20030059773 Immunomodulatory formulations and methods for use thereof
03/27/2003US20030059765 Compositions and methods for providing a protein to a virion
03/27/2003US20030059470 Dispersions for the formulation of slightly or poorly soluble agents
1 ... 1204 1205 1206 1207 1208 1209 1210 1211 1212 1213 1214 1215 1216 1217 1218 1219 1220 1221 1222 1223 1224 ... 1798